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MAJOR ARTICLE
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Infection, Sepsis, and Infectious Death in Pediatric
Acute Myeloid Leukemia (AML): Results From
the Canadian Infections in AML Research Group
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Background. Infection continues to be a major problem for children with acute myeloid leukemia (AML).
Objectives were to identify factors associated with infection, sepsis, and infectious deaths in children with newly
diagnosed AML.
Methods. We conducted a retrospective, population-based cohort study that included children ≤18 years of
age with de novo, non-M3 AML diagnosed between January 1995 and December 2004, treated at 15 Canadian
centers. Patients were monitored for infection from initiation of AML treatment until recovery from the last cycle
of chemotherapy, conditioning for hematopoietic stem cell transplantation, relapse, persistent disease, or death
(whichever occurred ﬁrst). Consistent trained research associates abstracted all information from each site.
Results. 341 patients were included. Median age was 7.1 years (interquartile range [IQR], 2.0–13.5) and 29
(8.5%) had Down syndrome. In sum, 26 (7.6%) experienced death as a ﬁrst event. There were 1277 courses of
chemotherapy administered in which sterile site microbiologically documented infection occurred in 313 courses
(24.5%). Sepsis and infectious death occurred in 97 (7.6%) and 16 (1.3%) courses, respectively. The median days
of corticosteroid administration was 2 per course (IQR, 0–6). In multiple regression analysis, duration of corticosteroid exposure was signiﬁcantly associated with more microbiologically documented sterile site infection, bacteremia, fungal infection, and sepsis. The only factor signiﬁcantly associated with infectious death was days of
corticosteroid exposure (odds ratio, 1.05; 95% conﬁdence interval, 1.02–1.08; P = .001).
Conclusions. In pediatric AML, infection, sepsis, and infectious death were associated with duration of corticosteroid exposure. Corticosteroids should be avoided when possible for this population.
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PATIENTS AND METHODS
We conducted a retrospective, population-based cohort study
that included children with primary AML diagnosed and
treated at all 15 Canadian centers that care for children with
cancer in each province except for Saskatchewan. The
Research Ethics Boards at The Hospital for Sick Children and
all participating institutions approved the study.
Study Sample

We included children and adolescents diagnosed with de novo
AML between 1 January 1995 and 31 December 2004 who
were ≤18 years of age at diagnosis. Children with Down syndrome were included. We excluded those with acute promyelocytic leukemia, secondary AML, previous diagnosis of
immunodeﬁciency, and children with Down syndrome receiving only low-dose cytarabine.
Patients were monitored for infection (time period at risk)
from initiation of AML treatment until hematopoietic recovery
from the last cycle of chemotherapy, conditioning for

hematopoietic stem cell transplantation (SCT), relapse, persistent disease, or death (whichever occurred ﬁrst). Consistent
trained clinical research associates traveled to each site to abstract and code the relevant information.
Outcome Measures

All infections were reviewed by an adjudication subcommittee,
and classiﬁcation occurred by consensus. The rates of sterile
site invasive infection, [9] clinically documented infection, and
fever of unknown origin were expressed as number of events
during the time period at risk. Similar to others [10, 11], positive cultures with common contaminants, such as coagulase
negative Staphylococcus, were only considered true infection if
there were ≥2 positive cultures within the same episode or if
the infection was associated with sepsis. Sepsis was deﬁned as
systemic inﬂammatory response syndrome in the presence of
suspected or proven infection and organ dysfunction according to international consensus guidelines [12, 13]. Classiﬁcation of clinically documented infection was based on the
Centers for Disease Control and Prevention (CDC) deﬁnitions
of nosocomial infections [14]. Fever of unknown origin was
deﬁned as a fever occurring in the absence of a positive microbiology result or clinical infection.
Potential Predictors

Potential predictors were as follows: (1) Child characteristics
at diagnosis (age, Down syndrome and obese vs nonobese);
(2) Treatment characteristics ( protocol type categorized as
non-Down’s speciﬁc Pediatric Oncology Group (POG), Children’s Cancer Group (CCG) or UK Medical Research Council
(MRC) protocols and Down syndrome–speciﬁc protocols, registration on AML trial, diagnosis prior to 1 January 2000, and
cumulative dose of cytarabine in grams/m2); (3) Course characteristics (neutropenia at the start of the course, neutropenia
>15 days (threshold chosen a priori), days corticosteroids
were administered for any reason, and dose of corticosteroids
in 10 mg/m2 of dexamethasone equivalents); and (4) Supportive care (co–trimoxazole and ﬂuconazole prophylaxis). In the
model of fungal infection, days of broad-spectrum intravenous
antibiotics, meropenem and vancomycin, were also examined.
Only systemic (and not topical) corticosteroid exposure was
examined. Corticosteroids, including hydrocortisone, prednisone, and methylprednisolone, were converted to dexamethasone equivalents by dividing the dose of corticosteroid
administered by the equivalent pharmacologic dose (eg, 26.7
for hydrocortisone and 6.7 for prednisone) [15]. Obesity was
deﬁned as ≥95% percentile for age and sex according to the
CDC for those at least 2 years of age [16]. The Children’s Oncology Group protocol AAML03P1 [17] was classiﬁed as
MRC-based.
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Children with acute myeloid leukemia (AML) are at substantial risk of mortality from invasive bacterial and fungal infections [1]. Efforts from multiple cooperative groups have
attempted to quantify the infectious burden in pediatric AML
and to identify factors associated with infections [2–8].
However, these reports are limited because of the inability to
differentiate true infections versus likely contaminants, the inconsistent classiﬁcation of clinically documented infection and
sepsis, and because of the small number of explanatory variables collected. These issues are important if the goal is to accurately identify factors associated with infectious morbidity
and mortality.
Identiﬁcation of clinical variables that can predict the risk
of invasive infection is important. First, knowledge of treatment variables associated with infection may provide data to
support targeted prophylactic strategies. For example, prophylaxis could be used for children with a particular characteristic
or during speciﬁc treatment courses. Second, this knowledge
may aid in supportive care recommendations for future children with AML. Third, the study of genetic associations has
increased greatly over the last few years. To conﬁdently be able
to determine if genotype has an independent contribution to
outcomes, development of a robust model that adjusts for clinical covariates is critical.
To overcome the previous limitations in the literature, we
conducted a population-based retrospective cohort study in
Canada with careful collection and review of infection outcomes. Our primary objectives were to identify factors associated with infection, sepsis, and infectious deaths in children
with newly diagnosed AML.

Statistics

Table 1. Demographics, Treatments, and Supportive Care of the
Study Cohort (N = 341)
Demographic
Child characteristics at diagnosis
Male (%)
Median age in years (IQR)
Down syndrome (%)
Body mass index (%) (n = 250)a
Obese
Normal weight
Underweight
Median white blood cell count (×109/L) (IQR)
Median absolute neutrophil count (×109/L) (IQR)
(n = 326)

168 (49.3)
7.1 (2.0, 13.5)
29 (8.5)
30 (12.0)
199 (79.6)
21 (8.4)
17.1 (5.9, 60.6)
1.6 (0.4, 4.2)

FAB AML morphology (%)
M0

7 (2.1)

M1

49 (14.4)

M2
M4

81 (23.8)
68 (19.9)

M5

60 (17.6)

M6
M7

7 (2.1)
42 (12.3)

Otherb

27 (7.9)

Central nervous system involvementc (%) (n = 288) 75 (26.0)
Cytogenetics (%)

RESULTS
Figure 1 illustrates the ﬂow of patients; 395 patients were assessed for eligibility and 341 patients were included. Table 1
illustrates patient demographics. The median age was 7.1 years
(interquartile range [IQR]: 2.0 to 13.5) and 29 (8.5%) had
Down syndrome. The most common therapeutic protocols
were POG followed by CCG and MRC. Of the 341 children,

Value

t(8;21) (q22;q22) (AML1/ETO)

40 (11.7)

Inv16 (p13q22) or t(16;16)(p13;q22)
(CBFβ/MYH11)

13 (3.8)

Normal karyotype

80 (23.5)

11q23 (MLL) abnormalities
Monosomy 7

41 (12.0)
10 (2.9)

Unknown

50 (14.7)

Treatment and supportive care
Protocol (%)d, non–Down syndrome specific
POG

163 (48.3)

CCG
MRC

98 (29.1)
40 (11.9)

Othere

26 (7.7)

Down syndrome–specific protocold
Registered on study (%)d

10 (2.7)
89 (26.4)

Median No. of chemotherapy courses started
(IQR)
Received G-CSF (any indication) (%)

4.0 (2.0, 5.0)

Received intravenous immune globulin (%)

166 (48.7)
26 (7.6)

Abbreviations: AML, acute myeloid leukemia; CCG: Children’s Cancer Group;
FAB, French-American-British; G-CSF granulocyte-colony stimulating factor;
IQR: interquartile range; MLL, mixed lineage leukemia; MRC: Medical
Research Council; POG: Pediatric Oncology Group.
a

Only available for children ≥2 years of age.

b

Others were biphenotypia (n = 2), acute myeloid leukemia (AML) with
multilineage dysplasia (n = 3), isolated granulocytic sarcoma (chloroma)
(n = 2), and AML not further classified (n = 20).

Figure 1.
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c

Unknown (n = 53).

d

Four patients died before treatment started, and thus, n = 337.

e

Other: Ekert (n = 12), in-house protocol (n = 13), and Cancer and Leukemia
Group B (n = 1).
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Regression analyses were conducted at the course level. In
order to identify factors associated with rates of microbiologically documented sterile site infection, clinically documented
infection and fever of unknown origin, we conducted a repeated measures Poisson regression using PROC GENMOD in
SAS. Determination of factors associated with occurrence of
gram-positive, gram-negative, and fungal infections from
sterile sites was conducted with repeated logistic regression
analysis using generalized estimating equations. These approaches were used because each child could experience multiple courses of chemotherapy. Variables signiﬁcant in
univariate analysis were included in multiple regression analysis. Because of high correlation, only corticosteroid duration
and not dose and only Down syndrome and not Down syndrome–speciﬁc protocol were included if both met criteria for
entry. Similarly, in the model of fungal infection, only days
receiving broad-spectrum intravenous antibiotics were used
and not the other measures of antibiotic exposure. All tests of
signiﬁcance were 2-sided, and statistical signiﬁcance was
deﬁned as P < .05. Statistical analysis was performed using the
SAS statistical program (SAS-PC, version 9.3; SAS Institute
Inc, Cary, North Carolina).

Table 2.

Multiple Regression Analyses of Infection Outcomesa
Estimate (95% CI) P value

Outcome and Potential Predictors
Microbiological sterile site infection

Rate ratio

Down syndrome
0.75 (.37, 1.50)
Treatment protocol, non–Down syndrome specific

Sterile site fungal infection

.050
.117

Greater than 15 d with neutropenia

1.69 (.50, 5.72)

.400

Days receiving corticosteroids
Days receiving broad spectrum
antibiotics

1.05 (1.01, 1.09)
1.04 (1.00, 1.08)

.013
.027

Reference
.096
.006

Cumulative dose of cytarabine (g/m )

1.04 (1.02, 1.05)

<.0001

Greater than 15 d with neutropenia
Days receiving corticosteroids

1.19 (.87, 1.64)
1.04 (1.03, 1.05)

.282
<.0001

Rate ratio
0.28 (.11, .75)
1.55 (1.21, 1.98)

Greater than 15 d with neutropenia

1.21 (.90, 1.62)

.211

Days receiving corticosteroids
Fluconazole prophylaxis

1.02 (1.01, 1.03)
1.46 (1.06, 2.02)

.002
.022

.011
.0005

Rate ratio

Down syndrome
Obese vs nonobeseb

1.41 (1.00, 2.00)
1.44 (1.03, 1.99)

.053
.031

Cumulative dose of cytarabine (g/m2)

1.02 (1.00, 1.04)

.019

Greater than 15 d with neutropenia
Days receiving corticosteroids

0.68 (.51, .91)
0.98 (.96, 1.00)

.010
.090

Down syndrome
Treatment protocol, non–Down
syndrome specific

Odds ratio
0.59 (.25, 1.39)

.226

.001

MRC

2.70 (1.72, 4.24)

<.0001

Cumulative dose of cytarabine (g/m2)
Greater than 15 d with neutropenia

1.05 (1.02, 1.07)
1.92 (1.35, 2.73)

<.0001
.0003

Days receiving corticosteroids

1.06 (1.04, 1.09)

<.0001

1.13 (.75, 1.71)
Odds ratio

.563

CCG

Reference
1.22 (.78, 1.92)

.379

MRC
Diagnosed prior to 1 January 2000

2.36 (1.37, 4.08)
0.90 (.59, 1.38)

.002
.634

Cumulative dose of cytarabine (g/m2)

1.05 (1.03, 1.08)

<.0001

Greater than 15 d with neutropenia
Days receiving corticosteroids

1.53 (1.04, 2.25)
1.06 (1.04, 1.09)

.030
<.0001

Sterile site gram-negative infection

POG
CCG

Reference
1.37 (.73, 2.57)

.326

MRC

1.26 (.64, 2.46)

.506

Neutropenia (ANC <0.5 × 109)
at start of course

1.38 (.78, 2.44)

.271

Greater than 15 d with neutropenia

1.97 (1.04, 3.76)

.039

Days receiving corticosteroids
Co-trimoxazole prophylaxis

1.07 ( 1.04, 1.10)
1.80 (.90, 3.61)

<.0001
.095

1.05 (1.02, 1.08)

.001

Days receiving corticosteroids

Abbreviations: ANC: absolute neutrophil count; CCG: Children’s Cancer
Group; CI: confidence interval; MRC: Medical Research Council; POG:
Pediatric Oncology Group.
a

Analyses were conducted using multivariable repeated measures Poisson
or logistic regression.
Obesity only available for children ≥2 years of age.

c

Reference
1.89 (1.29, 2.77)

Treatment protocol, non–Down
syndrome specific
POG

Odds Ratio

Infection-related mortalityc

b

POG
CCG

Co-trimoxazole prophylaxis
Sterile site gram-positive infection

Sepsis
Treatment protocol, non–Down
syndrome specific

Odds ratio

Treatment protocol, non–Down
syndrome specific
POG

Reference

CCG
MRC

2.18 (1.34, 3.56)
1.46 (.73, 2.93)

.002
.288

Greater than 15 d with neutropenia

2.55 (1.47, 4.43)

.001

Days receiving corticosteroids

1.04 (1.02, 1.07)

.001

Infection-related mortality is the univariate analysis because only one
variable met entry criteria for multiple regression.

26 (7.6%; 95% conﬁdence interval: 4.8%–10.4%) experienced
death as a ﬁrst event. Over the course of therapy, the cumulative incidence of any sterile site microbiologically documented
infection was 218 (63.9%), bacteremia was 185 (54.3%), and a
clinically documented infection was 263 (77.1%). Supplementary Appendix Table 1 illustrates the microbiologically documented infections on this study. Using the revised deﬁnition
of invasive fungal infection (IFI) from the European Organization for Research and Treatment of Cancer/Mycosis Study
Group [18], there were 38 proven IFIs, including 23 Candida
species, 7 Aspergillus spp, and 8 other or unspeciﬁed IFIs.
There were 8 probable IFIs.
There were 1277 courses of chemotherapy administered;
Supplementary Appendix Table 2 illustrates the course characteristics and the infection outcomes. Non-co-trimoxazole antibacterial prophylaxis was very rare and only observed in 3
courses (0.2%). Fluconazole prophylaxis was administered in
693 courses (54.3%). There were 313 courses with at least one
sterile site microbiologically documented infection (24.5%), 97
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Down syndrome–specific protocol
Neutropenia (ANC <0.5 × 109) at
start of course

Bacteremia

Odds ratio
2.30 (1.00, 5.28)
1.92 (.85, 4.34)

1.31 (.95, 1.80)
1.72 (1.17, 2.52)

Fevers of unknown origin

Estimate (95% CI) P value

Diagnosed prior to January 1, 2000
Neutropenia (ANC <0.5 × 109) at
start of course

CCG
MRC

Clinically documented infection

Outcome and Potential Predictors

.415

POG

2

Table 2 continued.
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DISCUSSION
In this large, population-based analysis including different treatment protocols, we made several key observations. First, corticosteroid exposure is an important risk factor for infection
outcomes and, more speciﬁcally, is independently associated
with both sepsis and infection-related mortality. Second, systemic corticosteroid exposure is common in pediatric AML, even
when the treatment protocol does not include corticosteroids.
Third, this study conﬁrms that high-dose cytarabine is associated with bacteremia and, in particular, gram-positive infection,
and that prolonged neutropenia continues to be an independent
risk factor for bacterial and fungal infection in addition to sepsis.
We found that corticosteroid exposure was associated with
higher rates of infection, sepsis, and infectious death. Although corticosteroid exposure has previously been determined to be a risk factor for IFI [19, 20], the relationship with
other infection outcomes is less well recognized. In a randomized study of 147 patients receiving allogeneic SCT for hematological malignancy, those randomized to receive 35 days of
methylprednisolone for graft-vs-host disease (GVHD) prophylaxis had a higher rate of infection, with bacteremia being the
most common type of infection [21]. Conversely, another randomized study of methylprednisolone prophylaxis in allogeneic SCT found that there were fewer infections in the
prophylaxis group although the study was difﬁcult to interpret,
given that the total amount of methylprednisolone received
was similar in the 2 study arms because of more acute GVHD
in the no prophylaxis group [22]. This study illustrates the importance of accounting for nonprotocol corticosteroid exposure in the evaluation of risk factors for infection outcomes.
Consistent with the literature, we found a higher risk of infection with longer duration of neutropenia [7, 23] and higher
cumulative dose of cytarabine [24, 25]. However, we also
found that obesity was not associated with infection outcomes,
a ﬁnding distinct from those of the CCG [8, 26]. It is difﬁcult
to know whether these differences are related to a different
population ( predominately American vs Canadian) or different methodological approaches in infection and other
outcome ascertainment.
In our study, Down syndrome was not associated with a
higher risk of infection or sepsis. This ﬁnding is in contrast to
most reports that have found Down syndrome to be an important risk factor for infection and infectious death [22]. In our
cohort, 10 of 29 children with Down syndrome were treated
on a Down syndrome–speciﬁc protocol. In univariate analysis,
we found that Down syndrome–speciﬁc protocol was associated with a lower risk of infection outcomes. It is possible that
our results may be explained by a lower dose intensity of
Down syndrome–speciﬁc protocols compared with non–
Down syndrome–speciﬁc protocols.
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courses with sepsis (7.6%), and 16 infectious deaths (1.3%).
The median number of days receiving any corticosteroid was
2 (IQR, 0–6). Supplementary Appendix Table 3 illustrates the
median duration and dose in mg/m2 of dexamethasone equivalents of corticosteroid exposure for those receiving POG-,
CCG-, or MRC-based treatment. For those receiving MRCbased treatment, which does not include corticosteroids as
chemotherapy, the median dose was 31.9 mg/m2 of dexamethasone equivalents.
Supplementary Appendix Tables 4–6 illustrate the univariate models of infection, sepsis, and infectious death. In terms
of patient characteristics, Down syndrome patients had a
reduced risk of microbiologically documented infection and
bacteremia. Obesity did not signiﬁcantly inﬂuence the development of documented infection, sepsis, or infectious death.
In terms of treatment variables, CCG- and MRC-based protocols were associated with more microbiologically documented
infection compared with POG protocols, and sepsis was significantly more common with CCG- vs POG-based treatment.
No differences in documented infection, sepsis, or death were
seen when comparing CCG and MRC protocols (data not
shown). The cumulative dose of cytarabine per course was
speciﬁcally associated with microbiologically documented infection, bacteremia, gram-positive sterile site infection, and
fever of unknown origin. In terms of nontreatment course
characteristics, neutropenia at the start of the course was not
associated with bacterial infections, sepsis, or infectious death
but was signiﬁcantly associated with clinically documented
infection and sterile site fungal infection. Greater days of receiving corticosteroids was associated with a higher risk of
microbiologically and clinically documented infection, bacteremia, sterile site gram-positive and gram-negative infection,
sterile site fungal infection, sepsis, and infectious death. The
only signiﬁcant factor associated with infectious death was
the duration of corticosteroid exposure. All measures of antibiotic administration were signiﬁcantly associated with fungal
infection.
Table 2 illustrates the multiple regression analyses of all outcomes. First, MRC protocols, in comparison to POG protocols, were associated with more microbiologically documented
sterile site infection and more bacteremia. Second, cytarabine
dose was independently associated with sterile site infection
and bacteremia and more speciﬁcally, gram-positive infection.
Third, duration of corticosteroid exposure was an independent
risk factor for microbiologically documented sterile site infection, bacteremia, both gram-positive and gram-negative infection, fungal infection, clinically documented infection, and
sepsis. Fourth, the 2 independent risk factors for sepsis were
prolonged neutropenia and duration of corticosteroid exposure. Finally, only duration of corticosteroid was associated
with infectious death.

Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online
(http://cid.oxfordjournals.org). Supplementary materials consist of data
provided by the author that are published to beneﬁt the reader. The
posted materials are not copyedited. The contents of all supplementary
data are the sole responsibility of the authors. Questions or messages
regarding errors should be addressed to the author.
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The major strength of our report is the rigor in identifying
infections, given that a common group of trained personnel
abstracted all infection data. Second, our ﬁndings are highly
generalizable and allow the comparison of protocols from different cooperative groups. Another major advantage of our
report is the approach; we examined factors associated with
outcomes at the course level and not at the patient level. This
approach has been advocated by others [25] and, very importantly, allowed us to evaluate factors that are expected to
change between courses such as chemotherapy attributes, duration of neutropenia, and administration of corticosteroids.
However, our study must be interpreted in light of its limitations. First, the number of infectious deaths was limited.
Second, there was heterogeneity in protocols and differences
in supportive care throughout the centers. However, this heterogeneity is also a strength in terms of generalizability and
the ability to identify how variability impacts on infection outcomes. In terms of protocol heterogeneity, because most cooperative groups build on previous studies in developing
successor trials, protocols within a cooperative group should
be more similar than protocols between different groups [27].
In terms of changes over time, we did not observe major difference in patients treated early vs late. Third, we do not know
the reasons corticosteroids were used; corticosteroids may be
used for a variety of reasons including for antiemetic control,
transfusion reaction prophylaxis, and to treat cytarabinerelated reactions. Corticosteroids may also be included as part
of the treatment protocol, such as with CCG-based therapy.
Although we attempted to control for confounding factors, it
is possible that corticosteroid use is indicative of more ill patients, rather than causally related to outcomes. Finally, we
conducted multiple analyses, and the P values must be interpreted cautiously in light of this repeated testing.
In conclusion, in pediatric AML, infection, sepsis, and infectious deaths were associated with duration of corticosteroid
exposure. Our analysis suggests that corticosteroids should be
avoided whenever possible for this population.
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Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod
tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim
veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea
commodo consequat. Duis aute irure dolor in reprehenderit in voluptate
velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat
cupidatat non proident, sunt in culpa qui o cia deserunt mollit anim id
est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed
do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim
ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip
ex ea commodo consequat. Duis aute irure dolor in reprehenderit in
voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint
occaecat cupidatat non proident, sunt in culpa qui o cia deserunt mollit
anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing
elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi
ut aliquip ex ea commodo consequat. Duis aute irure dolor in
reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Excepteur sint occaecat cupidatat non proident, sunt in culpa qui o cia
deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet,
consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et
dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation
ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure
dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla
pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa
qui o cia deserunt mollit anim id est laborum. Lorem ipsum dolor sit
amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut
labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud
exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore
eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident,
sunt in culpa qui o cia deserunt mollit anim id est laborum. Lorem
ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor
incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam,
quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo
consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse
cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat
non proident, sunt in culpa qui o cia deserunt mollit anim id est
laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do
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eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad
minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex
ea commodo consequat. Duis aute irure dolor in reprehenderit in
voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint
occaecat cupidatat non proident, sunt in culpa qui o cia deserunt mollit
anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing
elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi
ut aliquip ex ea commodo consequat. Duis aute irure dolor in
reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Excepteur sint occaecat cupidatat non proident, sunt in culpa qui o cia
deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet,
consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et
dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation
ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure
dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla
pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa
qui o cia deserunt mollit anim id est laborum. Lorem ipsum dolor sit
amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut
labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud
exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore
eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident,
sunt in culpa qui o cia deserunt mollit anim id est laborum. Lorem
ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor
incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam,
quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo
consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse
cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat
non proident, sunt in culpa qui o cia deserunt mollit anim id est
laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do
eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad
minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex
ea commodo consequat. Duis aute irure dolor in reprehenderit in
voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint
occaecat cupidatat non proident, sunt in culpa qui o cia deserunt mollit
anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing
elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
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Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi
ut aliquip ex ea commodo consequat. Duis aute irure dolor in
reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Excepteur sint occaecat cupidatat non proident, sunt in culpa qui o cia
deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet,
consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et
dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation
ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure
dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla
pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa
qui o cia deserunt mollit anim id est laborum. Lorem ipsum dolor sit
amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut
labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud
exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore
eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident,
sunt in culpa qui o cia deserunt mollit anim id est laborum. Lorem
ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor
incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam,
quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo
consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse
cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat
non proident, sunt in culpa qui o cia deserunt mollit anim id est
laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do
eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad
minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex
ea commodo consequat. Duis aute irure dolor in reprehenderit in
voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint
occaecat cupidatat non proident, sunt in culpa qui o cia deserunt mollit
anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing
elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi
ut aliquip ex ea commodo consequat. Duis aute irure dolor in
reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Excepteur sint occaecat cupidatat non proident, sunt in culpa qui o cia
deserunt mollit anim id est laborum.
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